This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
  • 00
  • 00
  • 00
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering



Op2Lysis is a French-Belgian biotech company focused on the development of innovative new treatments for patients with cerebrovascular thrombotic diseases, looking to raise €8M EUR, to complete their €23M EUR Series A round. The proceeds will be used to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with supra-tentorial hemorrhagic stroke and (ii) develop their pipeline of thrombolytic agents, based on their unique NANOp2Lysis® platform, for indications such as infra-tentorial hemorrhagic stroke and ischemic stroke. • Op2Lysis is offering a breakthrough technology accessible to any hospital in order to reduce patient dependency and associated costs. Development choices are based on an existing documented clinical proof of concept. Op2lysis researches and develops innovative medicines whose purpose is to lyse hematoma and blood clot formed during thrombosis in the brain. • Op2Lysis is led by an experienced team that combines biopharma, technology, cardiovascular/neuroscience, clinical and project management and business expertise, and backed by a robust BoD and renown SAB. • Op2Lysis’ team has demonstrated the capacity to raise equity capital (€2.1M) and to secure non-dilutive funds (€15M) from European Innovation Council accelerator, bpifrance and Wallonia funds. • De-risked pharmaceutical (industrial manufacturing process scale-up) and clinical developments (pre-IND meeting already held with the FDA, clinical study design successfully applied previously). • Potential for accelerated/conditional approval as soon as 2026, markets exclusivity and favorable pricings in a favorable competitive landscape (unmet medical need for a life-threatening condition for which there is no approved treatment yet) - Orphan Drug Designations already granted by the FDA and the EMA • Sales potential (€ 1.4 Billion peak sales anticipated by 2032) and strategic partnerships to monetize assets offer attractive exit options (IPO or M&A)